pre-miRNA Information | |
---|---|
pre-miRNA | hsa-mir-155 |
Genomic Coordinates | chr21: 25573980 - 25574044 |
Description | Homo sapiens miR-155 stem-loop |
Comment | Human mir-155 is predicted based on homology to a cloned miR from mouse (MIR:MI0000177) . |
RNA Secondary Structure | |
Associated Diseases |
Mature miRNA Information | |||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mature miRNA | hsa-miR-155-3p | ||||||||||||||||||
Sequence | 43| CUCCUACAUAUUAGCAUUAACA |64 | ||||||||||||||||||
Evidence | Experimental | ||||||||||||||||||
Experiments | Cloned | ||||||||||||||||||
SNPs in miRNA |
|
||||||||||||||||||
Putative Targets |
miRNA Expression profile | |
---|---|
miRNAs in Extracellular Vesicles |
|
Circulating MicroRNA Expression Profiling |
Biomarker Information |
|
---|
Gene Information | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gene Symbol | IRAK3 | ||||||||||||||||||||
Synonyms | ASRT5, IRAKM | ||||||||||||||||||||
Description | interleukin 1 receptor associated kinase 3 | ||||||||||||||||||||
Transcript | NM_001142523 | ||||||||||||||||||||
Other Transcripts | NM_007199 | ||||||||||||||||||||
Expression | |||||||||||||||||||||
Putative miRNA Targets on IRAK3 | |||||||||||||||||||||
3'UTR of IRAK3 (miRNA target sites are highlighted) |
>IRAK3|NM_001142523|3'UTR 1 ATTCTACCAGAAGATAAAGAAAAAAGCAAGTATTGCATAGGCACCTGAGCATAGGTATGACCTTGGGAAGACATTGGCTC 81 CATAAGCAATGCCAAGAGAATGATCAATAGTGAGTTTGGGTGATGCAGATAAACAATCTGGATAATTCCATTTCTTTTTT 161 CCCAAACCCTCAAACAGAGTGCCTTAAAAAATTGTTTTATCAGGATAATTGTCTCATGACCAAATCCACGCTCAATTAGA 241 GCCATTCAAAATTCCTTAAGATCATGGGTTCTGACTTCAGCCAAACAAAACAATCAAAACCTACCAAAAAGGGACTGGAT 321 TGTAATGTCCTCTCCATCATCCTCAGTGTGAGTCCTCAGAGCCTCCATCTGCCAAGAACATTCAGTTGGATTCCATCGTT 401 TGGTTTAGCTTGCTTGCACGGGTTGTAGGAAATGTCTAATTTGTAAATGTTAATAGATACCTTTGGAAAGAATCACCTTG 481 TTATTCTGATTGACCCCTCTTGTTTTTTGGTTAATCCCTGACTAGCCTGCTTGTCTGAAAATGAGCCAGGTTCACCCTTA 561 GCTACGGCATGCTCTGGGTTGAAAGGGGATTTCTTCCCAAGATCTATCCTAAACTCTTAGGACAGTTTATCCTGTATTGA 641 CTATTATTACAGCTTTTTAAAAACAGACTTAGTGACCTATTATATCTTAAGGAGACTATGTGAAATGTCCATCAAGTAAT 721 TTTTATTCCTGAGAAAATGGCTGGTCAAGGGCCTAGGTCAGCTTTTTGTTTAATCTACACCTTTCAACTCTGGGCCTTCA 801 TTCCTGCTGTTTCTTGGATCTCCCTCTTTTGAAATCCTACCAATCATCAGAGCTCTACAAAACAGCCACCTCCTGGAAGC 881 TTCCCTAATCTCTACAACCAGAAGTACTCCCTTTATCAGTATTTCCACAGCAATTTCTTTGTATTTCTATTTTATATTTA 961 TCACTTTCTGAATTATATCAAAGCTGCTTGTCTTATCTCTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCATCCAGGCT 1041 GGAGTGCAGTGGCACAATCTCGGCTCACCGCAAGGTCTGCCTCCCGGGTTCACGCCATTCTCCTGCCTCAGCCTCCCGAG 1121 TAAAGGTGGGACTACAGGCGCCCGCCACTACGCCCGGCTAATTTTTTGTATTTTTAGTAGAGACGGGGTTTCACCATGTT 1201 AGGCAGGATGGTCTCGATCTCCTGACCTCATGATCCGCCTGCCTGGCCTCCCAAAGTGCTGGGATTACAGGCGTGAGCCA 1281 CCGCGCCCAGCCTTCATCTCTTTTACTAGGTTGTAAACTCCCTATATTAGTTTTCTATTGTTTTTGTAACACATTATCAC 1361 AAATTTAGTGACTTAAAGTAACATAAATTAATTATTTTGCAGTTCTGGAGGTCAGAATTCCTTAGCATTCTTTCTGGAGG 1441 CTGTTGGGGAGAACTCACTGCCTTGCCTTTTCCAGCTTCTAGAGGCCACCTGCCTTCTTTGGCTCATGGCCTCTTCCTCC 1521 GTCTTCAAAGCCAGCAACGTGACATTTCAGATCTCCCTCTCTCTGTCTGTCTCACCGCATCTCTTCACTACCCTCTTCCT 1601 CTCATTCTGGCCCTTCTGCATGTCTTTTATAAAGACCTTTGTGATTTCACTGGGCCCACTCATATAAGCCAGGAAAATCT 1681 CTGTGTCTCAGATCCTTAATTTAATTACACCTGCAAAGTCCGTTTTCTCGTGTAAAGTAACATATTCACAGGTTTCTGGA 1761 ATTGGGACGTGGACATCTTCGGGGGACCATTACTCTGTCTGTCATACTCCCTGAGTGTGTAAGGGCCATCTCTTCAGAGC 1841 CTAATGTGTCATCCTACACAGAGCAGGTGTTTCCTTATAAATTAAGTTGAATTAAATTACCCCTATGAAGCCACATAATC 1921 AATAATTCAGCTATAATAAACATTGCCGAATAAATTAACAAAGGGAGGATAATGACTCCTTATGATGATGGATAGAAACA 2001 CTGAAGAAAACCATTTTCAGAGGATTTACTGAATTTTCCTCTCCAAGGAGCTTGTAATAGAAGGGTAAACCTCTAGTTTC 2081 TTGTCCAGCAGAGGAATAGGCTCATGTCTTTTGTTTTATTTTATTTTTTTGGTGAGTCAGTATGGTTGGGTTAATCATAT 2161 TCACATTAGATTCCATGTTGAAGAACAACTAATCAAAGAAGAAAATCATCAGGAATCAGGGTGAGATTAACAGACCAAGG 2241 TCAGAAACATGGAGTTACAATTTTCCAAAAAAGCACGAAGTGAGATTAAAACCACAGTAAGTCTTAGTCTGACTGACAGG 2321 CTTTATACAGGCCCTCGGTAAGCAGTTGGGAGAACCCATGCCCACCACTGCTCTGTACGGTATCTGGCTGCTCAGAGCTC 2401 TCTGATTCACAAAAGAGATCATCAAGAATTGACTCTGTGTTAAACTGTTTTTCACTTAGAATATGGACCCCCACCAATAC 2481 ATTCAATGAAGGGTCATTAAGGAAGCTCTGATTAACACCAGGCCCATGCAGTTACTCCGCACATATAATCTGTGGGTATT 2561 ATGTTGATTTGAACTTGCTTAGCTGACTTAAAGCAGGGTTTCTCAAACTGTAGTATGCATCAGAATGACTTGGAAAGCTG 2641 GTTAAAAACGCAGATTGCTGGGTCCACCCAGCTTCTGATGCAATAGGTCTGGGGTTAGAAATTTTGCTTTCTAATGAGTT 2721 CCCAGGTGATGCTGATGCCAATGATGTGAAGCCCGCTCTTCACATCCGTGAAAATCGCTGCCTTAAGGTGCTCTTAAATT 2801 GTTATAGATTGGTAGATCCTACCTTTCCATCACTGGTATGTTTTTTGAGAAAAGGATCCTTTCTTTTCATTCTGTTATAT 2881 TCATCCTATTACATAGGATGTTGGTTAGCACAGAGTGGGAGCTCTAGAAAGATTGTTGACCAATCATCTTATTGACTAGA 2961 CCATCTTTCTAGAGTATAACTATTTTGGACACCTCAAAGATGAAGTCAGATAAGCTGGCAGTGACCTGATTAACGTTGTG 3041 GTAAGCAGATGCCACTGTGGCTGGGAAGTACCAAATCTTCTGTTGAGTGATTCAGTCTTCCTGACTAGATTTGCCTTCTA 3121 GTGGGTGTATTAATAAGCGTTAGTTGATATGAATTAAATGTTGCAACTTTCTATGGGTAATAAGAGGATACCTTTATAGT 3201 TTCATGATGTGGAGACCAAGATACATAAGAAAGCAAGAATGAGTCTCCGGGTGTTCCCTCTGATCAGCAAACATGAATTC 3281 ATAATTTCATTTACTCTCATTTTTGTAATGCACTCTGAGCAATCCTCCAGGCAGATCCTATTTACTAAGCTTCAGGCTTT 3361 TGTCCCATTTTATAATGCCCAAACACATGGAGAAAACATTTTGTTGTTTTTAAAAACAGGTATGGGATTTCTGATATAAT 3441 CAATTTTATTGACTTCTTGGGAGTTGTAATGATCTGTGACTCACTGCATAATATTGTAGTTTTATAGGGTGGCACATCAC 3521 CCTGTGTAAAACAACTTTAATGACCTGAGGACTGATGAGTACAGGAAGTGAGGTTTATCATGAGTAGCATTTATTAAGCA 3601 TCTGCTAGAATCAAAGCACTGCATTAGCTACTAAGGTACAAAGTAAGACACAGTTTAATAAGGAAGACAGGGCATCTACC 3681 CAAGTCAACAGTTCAGTGACATCTGTTATTTGAACCACACACCAATGCAACCGAAGTAAATGCTGAAAGGGTGAGAAGAA 3761 GGAATAGATTACTATGCATTTTTGAGAGGATGAAGAAGGCTTCTTGGAGAAGGTTTCTGAAAAGAGATACGGAATTAAGA 3841 GAAATAGAAAAGAGCACTGACGAAGCACTCAGGATGGCTATTCAAGGAATTGGGGATCCACAGCAGCTGTGCACAACCAT 3921 CCCTAATGCCAGAAAAATGGGGTAAGGGTGAAGGGAACTGGGTCTAGAGCTTTGCATGTTTTTTTCTGGTTAACCCTTAG 4001 AGTCACCCTGAAGGTGTGGATCCCATCTTATAATAAGGTGAGGACACTGAGTCAGGAAACTAACTTGCTAAAATCAAGTC 4081 CTCCCAGTCCTCCCATCAGGTCCTTCCAGATCTGGAGGAGCCAGGATTTGAACTCACATTTGTCTGACTTCAAAATCCAT 4161 GCTTTTTCTTGTGTTCCAAATTGCACAATGGAGTCACTGCCAGTTCAAGCTCCTATGAAAAGGGATGGATGTGAAAAGTC 4241 ATTTGTTGATTCCACAGATTTTTAGTAGGTACCATGTCTCCTGCCTTTATCACTATCCTACTCCTCTGCTACAACTTCTC 4321 TGCTACAGGCACCCACTGCAGTTACTTGATATGAGTTAAATGAATCCATCCATCCAAACTTCCATTCATTGAATAAATAC 4401 TTAGCAATGGCTTCCTTTGTATCAGGCACTATTCTAGGAGCTGGGGCTACAGTGCAGATGGAAACCAGCAAAGCTCACTG 4481 CCCTCATGGAGCTTATATGTAAGTGAATAAATCTCAGGGTGGTTCTCCTGTCATAGGTCCTGGCTCCTCTGCCAGCTCTT 4561 CCAAATGGGTTCAGAGAGGTTTTCTCCTTGTCCTGTTGTGTAACTGATAATCCCATGGTGGACCTCACTTTGCTATTCAT 4641 ATGCACTAAGTAGTTTATGGTGTGCTTTGTGGCTGGCAATTGTGACAGATTCTATTCTTCTATTGGTATGTGGTTTCTTT 4721 GGGGCATTTGTTTGGATACTGATGGCATCTTCCGGGGGTCTGAGGCACCTACACAAACCTCAGGTCACTATCACGTGATA 4801 CTGGAGTTGCCTGTTAAATTATATTTCTTCTTCCACAAAACTGCAGGTTCCCTGAGGGAAAGGTCTATGTCCTGCTCATT 4881 TTTGGATCCCTAATGGCTGGCACAGTACCTGGTGCATAATATGGTTCAACAAATATTTGTAAAATGAATGAATCAAATAG 4961 TCCTTCAAAGCATCTTCAGAATCAAGATTGTCATCTAGATTGCACCCGAAGTTTATCTTTCTAGTATTCAGAATATAATC 5041 AATCATTGCTTAAATTATTCCATTTCATCATTCTTGAATAAAAGCTACTAATTTTAAATACTAATATCTGAGATATCTTC 5121 GAAAAGAAGATTAGTCGTTGTATGTGTTGCTTATAAATTTTCTCTATGGTGGAAAATATTCCCAAACCATGTCTAAGCAA 5201 TGAAAAACCAGTGTTCTGGCAGGAAATAAACTGATGTTTGTTGTGTTTTGTATCTGTCTTCCCGTTCCAAATCATTTATA 5281 TATACTTGATGGTCTGTGGGCTTGACTTGCAAGTATTTTCCTGGGAGACATTTTTATTCAAAAGACCTGTATTGCCTGCC 5361 AAACCTTCATTTAAGAGACTCATTATGGATGTCATCTGCATCATTGCAAACTTTTCTGGTCGTCTCTATAAATAGCAAGA 5441 TAATATTTACAGAGTTTTACATTGGCTCTTGAATTTTAAAATATTCTTATAGACAAACATTAATTGGAATGGGGGGTAAG 5521 GAGGTAGGAATGGCTTACTTGCGGAAATGCAGGCTCATTGTTGTGTCTAGTAGGTGCTAGGTGCATTCACACATCTCTTA 5601 AGCTTTAAACAACCTATTGAGCCGGTTTCCATTTCCTTGATCTATTAGATTTAAAAAAATGAAGCATAAAGGAGTTGGCT 5681 CTTGCCCTAAGTCATACTACTGATGGAATGAGAATACAAACCAAAAACACTTTATTCAAGTCCAGGAAATATCTGCCTTG 5761 AAAAAGAATAACTTAAAAATTAAAAGTGTCCTCTATTTGAACATGAAAACAGCTAATAAAGATGTGTTATTTTATTTTAT 5841 TATTATTAATTTTGTCCTCCCATATTGGCAAAGATAAAGCAATTGACAAAAATGGAATTCTTGTTCAATACTGGCAGGAG 5921 TGAAAATTGGTAGAACCTTTCTAGAAGGCAATTTGGCAACATGTATGAAAACCTAAATGTTGATACACCTTTACCCAGCA 6001 GTTTGTTTAGGAATTTATCCTAATGAATAAAAGTTGTCCAAGTCTTCAAACATGAGCCCAAAGGTATATTTCATGATGTT 6081 TATGATATTAAAACATTGGAAACAACTGAAACATCCTTCAGTAAAAGATGGATTAAATAAATTCCATGCAGTTGTCATTT 6161 AAAAATATTTAGATATATGTTTATTGCTATGGATATATGTTCCCAAAATATTATTGAATCAAAAAGTAGACTACAGGATA 6241 TATGTTGAATATGAGCTCATTTATAACATTGAATATTTTAAGATAATGTATGTTTCATAGAGAGATCTTCACCAAATGTT 6321 AAGGATTTTTTTTTCTGGGCTGTGGTATTTGGGTGATCTTTACATTCTTCAGACTCATGTGTGTTTGAAACTTTTTATAA 6401 TGAACATATATCATTTTTATTAGAAAAGAATAAAGTTTTTGAAAAAAAAAAAAAAAAA Target sites
Provided by authors
Predicted by miRanda
DRVs
SNPs
DRVs & SNPs
|
||||||||||||||||||||
miRNA-target interactions (Predicted by miRanda) |
|
||||||||||||||||||||
DRVs in gene 3'UTRs | |||||||||||||||||||||
SNPs in gene 3'UTRs |
Experimental Support 1 for Functional miRNA-Target Interaction | |
---|---|
miRNA:Target | ---- |
Validation Method |
|
Conditions | HeLa |
Disease | 11213.0 |
Location of target site | 3'UTR |
Tools used in this research | TargetScan |
Original Description (Extracted from the article) |
...
"We have shown that miR-155* and miR-155 are differentially regulated by KHSRP and type I IFN. The type I IFN also causes more KHSRP activation by TLR7 through its induction of KHSRP expression
... - Zhou H; Huang X; Cui H; Luo X; Tang Y; Chen et al., 2010, Blood. |
Article |
- Zhou H; Huang X; Cui H; Luo X; Tang Y; Chen et al. - Blood, 2010
The recent discovery of microRNAs (miRNAs) has revealed a new layer of gene expression regulation, affecting the immune system. Here, we identify their roles in regulating human plasmacytoid dendritic cell (PDC) activation. miRNA profiling showed the significantly differential expression of 19 miRNAs in PDCs after Toll-like receptor 7 (TLR7) stimulation, among which miR-155* and miR-155 were the most highly induced. Although they were processed from a single precursor and were both induced by TLR7 through the c-Jun N-terminal kinase pathway, miR-155* and miR-155 had opposite effects on the regulation of type I interferon production by PDC. Further study indicated that miR-155* augmented interferon-alpha/beta expression by suppressing IRAKM, whereas miR-155 inhibited their expression by targeting TAB2. Kinetic analysis of miR-155* and miR-155 induction revealed that miR-155* was mainly induced in the early stage of stimulation, and that miR-155 was mainly induced in the later stage, suggesting their cooperative involvement in PDC activation. Finally, we demonstrated that miR-155* and miR-155 were inversely regulated by autocrine/paracrine type I interferon and TLR7-activated KHSRP at the posttranscriptional level, which led to their different dynamic induction by TLR7. Thus, our study identified and validated novel miRNA-protein networks involved in regulating PDC activation.
LinkOut: [PMID: 20852130]
|
MiRNA-Target Expression Profile | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
MiRNA-Target Expression Profile (TCGA) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
73 hsa-miR-155-3p Target Genes:
Functional analysis:
ID | Target | Description | Validation methods | |||||||||
Strong evidence | Less strong evidence | |||||||||||
MIRT005808 | IRAK3 | interleukin 1 receptor associated kinase 3 | 4 | 1 | ||||||||
MIRT082844 | ZNF460 | zinc finger protein 460 | 2 | 4 | ||||||||
MIRT256047 | UBE2K | ubiquitin conjugating enzyme E2 K | 2 | 4 | ||||||||
MIRT437787 | PTEN | phosphatase and tensin homolog | 2 | 1 | ||||||||
MIRT456168 | ZDHHC6 | zinc finger DHHC-type containing 6 | 2 | 2 | ||||||||
MIRT464916 | TXNIP | thioredoxin interacting protein | 2 | 4 | ||||||||
MIRT475559 | HNRNPF | heterogeneous nuclear ribonucleoprotein F | 2 | 2 | ||||||||
MIRT499608 | DNAJA1 | DnaJ heat shock protein family (Hsp40) member A1 | 2 | 8 | ||||||||
MIRT504220 | MYO6 | myosin VI | 2 | 4 | ||||||||
MIRT504256 | C1orf147 | chromosome 1 open reading frame 147 | 2 | 4 | ||||||||
MIRT507642 | CREBRF | CREB3 regulatory factor | 2 | 2 | ||||||||
MIRT522858 | KIAA1551 | KIAA1551 | 2 | 2 | ||||||||
MIRT527505 | MYD88 | myeloid differentiation primary response 88 | 5 | 2 | ||||||||
MIRT530713 | ORMDL3 | ORMDL sphingolipid biosynthesis regulator 3 | 2 | 2 | ||||||||
MIRT532851 | ZNF699 | zinc finger protein 699 | 2 | 2 | ||||||||
MIRT535952 | MIA3 | MIA family member 3, ER export factor | 2 | 2 | ||||||||
MIRT539041 | ATXN1L | ataxin 1 like | 2 | 4 | ||||||||
MIRT556391 | LUC7L | LUC7 like | 2 | 2 | ||||||||
MIRT558617 | CNOT6L | CCR4-NOT transcription complex subunit 6 like | 2 | 2 | ||||||||
MIRT559869 | ATXN3 | ataxin 3 | 2 | 2 | ||||||||
MIRT569208 | SHC3 | SHC adaptor protein 3 | 2 | 2 | ||||||||
MIRT573122 | C18orf25 | chromosome 18 open reading frame 25 | 2 | 2 | ||||||||
MIRT575076 | Ddit4 | DNA-damage-inducible transcript 4 | 2 | 2 | ||||||||
MIRT607597 | ABCF3 | ATP binding cassette subfamily F member 3 | 2 | 6 | ||||||||
MIRT609386 | PHEX | phosphate regulating endopeptidase homolog X-linked | 2 | 2 | ||||||||
MIRT610550 | MDN1 | midasin AAA ATPase 1 | 2 | 2 | ||||||||
MIRT612390 | TCF7L2 | transcription factor 7 like 2 | 2 | 2 | ||||||||
MIRT612910 | GTDC1 | glycosyltransferase like domain containing 1 | 2 | 6 | ||||||||
MIRT613314 | ARL5C | ADP ribosylation factor like GTPase 5C | 2 | 2 | ||||||||
MIRT613356 | ADAMTS5 | ADAM metallopeptidase with thrombospondin type 1 motif 5 | 2 | 4 | ||||||||
MIRT613541 | CLMP | CXADR like membrane protein | 2 | 2 | ||||||||
MIRT617029 | SYT6 | synaptotagmin 6 | 2 | 2 | ||||||||
MIRT618044 | MRVI1 | murine retrovirus integration site 1 homolog | 2 | 2 | ||||||||
MIRT619307 | KIRREL | kirre like nephrin family adhesion molecule 1 | 2 | 2 | ||||||||
MIRT623209 | MTFR1L | mitochondrial fission regulator 1 like | 2 | 2 | ||||||||
MIRT625448 | RANGAP1 | Ran GTPase activating protein 1 | 2 | 2 | ||||||||
MIRT634551 | MACC1 | MACC1, MET transcriptional regulator | 2 | 2 | ||||||||
MIRT640740 | EPB41 | erythrocyte membrane protein band 4.1 | 2 | 2 | ||||||||
MIRT640906 | RAB13 | RAB13, member RAS oncogene family | 2 | 2 | ||||||||
MIRT644025 | ZNF792 | zinc finger protein 792 | 2 | 2 | ||||||||
MIRT651489 | WT1 | Wilms tumor 1 | 2 | 2 | ||||||||
MIRT652037 | LINC00598 | long intergenic non-protein coding RNA 598 | 2 | 2 | ||||||||
MIRT669093 | CDK6 | cyclin dependent kinase 6 | 2 | 2 | ||||||||
MIRT696720 | WNT3 | Wnt family member 3 | 2 | 2 | ||||||||
MIRT698085 | TPM1 | tropomyosin 1 | 2 | 2 | ||||||||
MIRT703284 | GID4 | GID complex subunit 4 homolog | 2 | 2 | ||||||||
MIRT707183 | ARHGEF33 | Rho guanine nucleotide exchange factor 33 | 2 | 2 | ||||||||
MIRT710362 | CREB5 | cAMP responsive element binding protein 5 | 2 | 2 | ||||||||
MIRT713501 | DCAF17 | DDB1 and CUL4 associated factor 17 | 2 | 2 | ||||||||
MIRT717153 | LRRC3C | leucine rich repeat containing 3C | 2 | 2 | ||||||||
MIRT719038 | ATP1A1 | ATPase Na+/K+ transporting subunit alpha 1 | 2 | 2 | ||||||||
MIRT719489 | LSG1 | large 60S subunit nuclear export GTPase 1 | 2 | 2 | ||||||||
MIRT720284 | DPYSL3 | dihydropyrimidinase like 3 | 2 | 2 | ||||||||
MIRT732474 | NLRP3 | NLR family pyrin domain containing 3 | 2 | 0 | ||||||||
MIRT732620 | MS | multiple sclerosis | 1 | 0 | ||||||||
MIRT732968 | TGFBR2 | transforming growth factor beta receptor 2 | 3 | 0 | ||||||||
MIRT733063 | AGTR1 | angiotensin II receptor type 1 | 3 | 0 | ||||||||
MIRT733206 | ADAM10 | ADAM metallopeptidase domain 10 | 1 | 0 | ||||||||
MIRT733302 | CRP | C-reactive protein | 2 | 0 | ||||||||
MIRT734202 | PDCD4 | programmed cell death 4 | 3 | 0 | ||||||||
MIRT734467 | SIRT1 | sirtuin 1 | 2 | 0 | ||||||||
MIRT734701 | Foxo3 | forkhead box O3 | 1 | 0 | ||||||||
MIRT734889 | SP4 | Sp4 transcription factor | 2 | 0 | ||||||||
MIRT735047 | BATF | basic leucine zipper ATF-like transcription factor | 1 | 0 | ||||||||
MIRT735048 | SPI1 | Spi-1 proto-oncogene | 1 | 0 | ||||||||
MIRT735734 | PICALM | phosphatidylinositol binding clathrin assembly protein | 3 | 0 | ||||||||
MIRT735944 | TNF | tumor necrosis factor | 1 | 0 | ||||||||
MIRT736131 | MYLK | myosin light chain kinase | 2 | 0 | ||||||||
MIRT736780 | FOXP3 | forkhead box P3 | 1 | 0 | ||||||||
MIRT736781 | CEBPB | CCAAT/enhancer binding protein beta | 1 | 0 | ||||||||
MIRT736858 | WEE1 | WEE1 G2 checkpoint kinase | 2 | 0 | ||||||||
MIRT736873 | TLR3 | toll like receptor 3 | 2 | 0 | ||||||||
MIRT736902 | CFH | complement factor H | 2 | 0 |
miRNA-Drug Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
miRNA-Drug Resistance Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|